Abstract
Botulinum Neurotoxins have always existed in nature, but its paralytic effect on humans due to the consumption of poorly preserved food was not recognized until 18th century. There are 8 serotypes of botulinum neurotoxins (A, B, C, D, E, F, G, H). Serotype A have been the most recognized one and was initially developed for large scale production in 1940’s. The first batch for clinical use was produced by Edward Schantz, who collaborated with Dr. Alan Scott, an ophthalmologist, evaluating botulinum neurotoxin to treat strabismus. The process Schantz used had variability and led to inconsistent batch production. However, this process is still used by various manufacturers of commercial botulinum neurotoxin products as the foundation. These manufacturers have refined the manufacturing of botulinum neurotoxins by implementing new advanced techniques, including better potency assays. Despite the improvements in the manufacturing process, botulinum neurotoxins are still one of the most potent molecules and therefore, require special handing and additional safety/security measurements during production.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Alam M, Dover JS, Arndt KA (2002) Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative. Arch Dermatol 138(4):510–514
Allergan (2012) Allergan receives positive opinions for first-of-its-kind, fully in vitro, cell-based assay for BOTOX® and VISTABEL®; Allergan Press Release. https://www.businesswire.com/news/home/20120222006363/en/Allergan-Receives-Positive-Opinions-First-of-Its-Kind-Fully-vitro
Allergan (2013) BOTOX® (onabotulinumtoxinA) [prescribing information]. Allergan, Irvine
Barash JR, Arnon SSA (2014) Novel strain of Clostridium botulinum that produces type B and type H. J Infect Dis 209:183–191
Brin M, James C, Matlman J (2014) Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics 2014(8):227–241
Centers for Disease Control and Prevention (2009) Biosafety in microbiological and biomedical laboratories, 5th edn. US Department of Health and Human Services, Washington
Erbguth FJ (2007) From poison to remedy: the chequered history of botulinum toxin. J Neural Transm 115(4):559–565
Fan Y, Barash JR, Lou J, Conrad F, Marks JD, Arnon SS (2016) Immunological characterization and neutralizing ability of monoclonal antibodies directed against botulinum neurotoxin type H. J Infect Dis 213:1–9
Fervert J, Ahn KY, Park MY, Sunga O (2018) Comparison of botulinum neurotoxin type A formulations in Asia. Clin Cosmet Investig Dermatol 2018(11):327–331
GenomeWeb (2011) FDA approves Allergan’s cell-based assay for Botox. https://www.genomeweb.com/archive/fda-approves-allergans-cell-based-assay-botox#.XS_x0OhKhyw
Keller JE (2006) Recovery from botulinum neurotoxin poisoning in vivo. Neuroscience 139:629–637
Klein AW (1998) Dilution and storage of botulinum toxin. Dermatol Surg 24(11):1179–1180
Nigam PK, Nigam A (2010) Botulinum toxin. Indian J Dermatol 55(1):8–14
Pickett A, Mewies M (2009) Serious issues relating to the clinical use of unlicensed botulinum toxin products. J Am Acad Dermatol 61(1):149–150
Rossetto O, Pirazzini M, Montecucco C (2014) Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol 12:535–549
Samizadeh S, De Boulle K (2018) Botulinum neurotoxin formulations: overcoming the confusion. Clin Cosmet Investig Dermatol 11:273–287
Scaglione F (2016) Conversion ratio between Botox®, Dysport®, and Xeomin® in clinical practice. Toxins 8(3):65
Schantz EJ, Johnson EA (1997) Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med 40(3):317–327
Shenot PJ, Mark JR (2014) Intradetrusor onabotulinumtoxinA injection: how I do it. Can J Urol 20(1):6649–6655
Ton J, Patel H, Bates R, Ahmad WM (2015) Process and system for obtaining botulinum neurotoxin; United State Patent US 8,932,827 B2; Patent Date 13 Jan 2015
Truong D, Hallett M (2013) Manual of botulinum toxin therapy, 2nd edn. Cambridge University Press, Cambridge
Walker TJ, Dayan SH (2014) Comparison and overview of currently available neurotoxins. J Clin Aesthet Dermatol 7(2):31–39
Waters T (1992) The fine art of making poison. Discover Magazine, August 1992. discovermagazine.com/1992/aug/thefineartofmaki93
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Hasan, F. (2019). Manufacturing and Clinical Formulations of Botulinum Neurotoxins. In: Whitcup, S.M., Hallett, M. (eds) Botulinum Toxin Therapy. Handbook of Experimental Pharmacology, vol 263. Springer, Cham. https://doi.org/10.1007/164_2019_311
Download citation
DOI: https://doi.org/10.1007/164_2019_311
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-66305-6
Online ISBN: 978-3-030-66306-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)